Clinical trials: Glucagon
Type 1 Diabetes Mellitus
Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab
This trial is designed to evaluate the effect of glucagon receptor antagonism by volagidemab (once weekly) on glucose recovery from hypoglycemia after treatment with glucagon in adults with type 1 diabetes.
- Trial name
- NCT06272695
- Testing
- Volagidemab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- REMD Biotherapeutics, Inc.
Type 2 Diabetes
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT07193459
- Testing
- HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy
Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men
The purpose of this study is to evaluate the safety and efficacy of the additional administration of scopolamine butylbromide, glucagon or NPO-11 following a single intragastric dose of NPO-11 during endoscopy in healthy adult…
- Trial name
- NCT00740324
- Testing
- NPO-11
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypoglycemia
Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons
BIOD-961 is a dry powder formulation of glucagon intended for use in a device that mixes (reconstitutes) the powder with liquid to make it easier for users to treat patients with severe hypoglycemia.
- Trial name
- NCT02403648
- Testing
- BIOD-961, Lilly Glucagon, Novo Glucagon
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Biodel
Type 1 Diabetes, Hypoglycemia
Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus
The purpose of this study is to determine whether ZT-01 increases the glucagon response to hypoglycemia in type 1 diabetes (T1D).
- Trial name
- NCT05007977
- Testing
- ZT-01 low dose, ZT-01 high dose
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Zucara Therapeutics Inc.
T2DM, Type 2 Diabetes Mellitus
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT05680129
- Testing
- Ecnoglutide high dosage, Ecnoglutide low dosage, Dulaglutide
- Where
- China
- Volunteers
- 623 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be…
- Trial name
- NCT02806960
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Women With Fertility Disorder
Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization
The success of in vitro fertilization is based mainly on uterine implantation embryo. An excessive uterine contractility may interfere with implantation by a movement of the embryo in the uterus.
- Trial name
- NCT01674283
- Testing
- Glucagon
- Where
- Canada
- Sponsor
- Clinique Ovo
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers
ZYD1 is a novel GLP-1 receptor agonist. The ZYD1 exhibits increased stability to proteolytic cleavage, especially against dipeptidyl peptidase-4 (DPP-IV). ZYD1 is a potent antidiabetic agent without gastrointestinal side-effects.
- Trial name
- ZYD1 (NCT01972893)
- Testing
- ZYD1
- Where
- India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight
The primary objective of this study is to evaluate the effect of a meal and evening dosing on the pharmacokinetics (PK) of KAI 7535 in healthy participants living with obesity or overweight.
- Trial name
- NCT07294898
- Testing
- KAI-7535
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kailera
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by…
- Trial name
- NCT07431086
- Testing
- Olatorepatide
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Type 1 Diabetes Mellitus
A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM
This is a single centre, double-blind, randomised, three-period crossover phase 1 trial in subjects with type 1 diabetes mellitus (T1DM). Each subject will be randomly allocated to a sequence of three treatments, i.e.
- Trial name
- NCT03176524
- Testing
- BioChaperone® glucagon formulation 1, BioChaperone® glucagon formulation 2, GlucaGen® HypoKit®
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Adocia
Obesity & Overweight, Mobility Disability
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
The primary objective of this study is to assess the effect of enobosarm on total body weight
- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Trial name
- PLATEAU (NCT07446998)
- Testing
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Where
- 13 sites in United States
- Volunteers
- 239 people
- Sponsor
- Veru Inc.
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01843127
- Testing
- Ranolazine, Exenatide
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in…
- Trial name
- NCT01733758
- Testing
- Albiglutide 30 mg weekly, Albiglutide 50 mg weekly, Liraglutide 0.9 mg daily
- Where
- 74 sites in Japan
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline
Hypoglycemia, Diabetes Mellitus, Type 1
A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to compare a needle-free treatment of hypoglycemia with nasal glucagon (study drug) to a marketed glucagon administered by the intramuscular (IM) route, in participants with type 1 diabetes mellitus…
- Trial name
- NCT03339453
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 2 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Insulin Hypoglycemia, Type 1 Diabetes Mellitus
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus.
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Trial name
- NCT03439072
- Testing
- G-Pen, Lilly Glucagon
- Where
- 6 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Xeris Pharmaceuticals